Our approach is to advance our CD19-Redirected ARTEMIS T Cell programs in relapsed/refractory and high-risk blood cancers first. Meanwhile, we are also developing multiple pipeline candidates using the “mark-and-kill” approach to address various types of solid tumors, as well as specificity challenges previously thought impossible to overcome.